HK1173141A1 - 用於預防 性傳播的殺微生物嘧啶或三嗪 - Google Patents
用於預防 性傳播的殺微生物嘧啶或三嗪Info
- Publication number
- HK1173141A1 HK1173141A1 HK13100210.9A HK13100210A HK1173141A1 HK 1173141 A1 HK1173141 A1 HK 1173141A1 HK 13100210 A HK13100210 A HK 13100210A HK 1173141 A1 HK1173141 A1 HK 1173141A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hiv
- triazine
- transmission
- preventing sexual
- microbicidal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02076897 | 2002-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1173141A1 true HK1173141A1 (zh) | 2013-05-10 |
Family
ID=29414777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13100210.9A HK1173141A1 (zh) | 2002-05-13 | 2013-01-07 | 用於預防 性傳播的殺微生物嘧啶或三嗪 |
Country Status (27)
Country | Link |
---|---|
US (4) | US7935710B2 (zh) |
EP (1) | EP1505980B1 (zh) |
JP (2) | JP4530848B2 (zh) |
KR (1) | KR101095358B1 (zh) |
CN (2) | CN102558070B (zh) |
AP (1) | AP2024A (zh) |
AR (1) | AR039540A1 (zh) |
AT (1) | ATE376420T1 (zh) |
AU (1) | AU2003240844B2 (zh) |
BR (2) | BRPI0310021B8 (zh) |
CA (1) | CA2486078C (zh) |
CY (1) | CY1110249T1 (zh) |
DE (1) | DE60317060T2 (zh) |
DK (1) | DK1505980T3 (zh) |
EA (1) | EA011298B1 (zh) |
ES (1) | ES2294291T3 (zh) |
HK (1) | HK1173141A1 (zh) |
HR (1) | HRP20041177B1 (zh) |
IL (1) | IL165174A (zh) |
MX (1) | MXPA04011392A (zh) |
NO (2) | NO331030B1 (zh) |
NZ (1) | NZ536976A (zh) |
PL (1) | PL215128B1 (zh) |
PT (1) | PT1505980E (zh) |
SI (1) | SI1505980T1 (zh) |
WO (1) | WO2003094920A1 (zh) |
ZA (1) | ZA200409984B (zh) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
BRPI0407329A (pt) | 2003-02-07 | 2006-01-10 | Janssen Pharmaceutica Nv | Derivados de pirimidina para a prevenção de infecção de hiv |
CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
PT1656372E (pt) | 2003-07-30 | 2013-06-27 | Rigel Pharmaceuticals Inc | Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina |
ITMI20031640A1 (it) | 2003-08-08 | 2005-02-09 | Mipharm S P A | Base per gel bioadesivi. |
UA93354C2 (ru) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
JP5095409B2 (ja) | 2004-11-24 | 2012-12-12 | ライジェル ファーマシューティカルズ, インコーポレイテッド | スピロ2,4−ピリミジンジアミン化合物およびその使用 |
EP1856135B1 (en) | 2005-01-19 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
ES2533258T3 (es) * | 2005-02-18 | 2015-04-08 | Janssen Sciences Ireland Uc | Derivados de óxido de 2-(4-cianofenilamino)pirimidina que inhiben el VIH |
SG137989A1 (en) | 2005-06-08 | 2008-01-28 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the JAK pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2007071199A1 (fr) * | 2005-12-22 | 2007-06-28 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Composes de 2,4-disubstituee amido-6-substituee-[1,3,5]triazine ou de 1,3-pyrimidine, leurs procedes d'elaboration, et preparations pharmaceutiques les contenant et leurs utilisations |
EP1991532B1 (en) | 2006-02-24 | 2017-01-11 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
RU2008152193A (ru) | 2006-06-15 | 2010-07-20 | Бёрингер Ингельхайм Интернациональ Гмбх (De) | 2-амино-4-аминоалкиленаминопиримидины |
AU2007257650A1 (en) | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha |
NZ577197A (en) | 2006-12-08 | 2011-02-25 | Irm Llc | Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors |
KR101475091B1 (ko) * | 2006-12-13 | 2014-12-22 | 에프. 호프만-라 로슈 아게 | 비뉴클레오시드 역전사 효소 억제제로서 2-(피페리딘-4-일)-4-페녹시- 또는 페닐아미노-피리미딘 유도체 |
DK2114901T3 (da) * | 2006-12-29 | 2014-06-30 | Janssen R & D Ireland | Hiv-inhiberende 6-substituerede pyrimidiner |
CN106045965A (zh) * | 2006-12-29 | 2016-10-26 | 爱尔兰詹森科学公司 | 抑制hiv的5,6‑取代的嘧啶类化合物 |
JP5600063B2 (ja) | 2007-10-19 | 2014-10-01 | セルジーン アビロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
KR101860057B1 (ko) | 2008-05-21 | 2018-05-21 | 어리어드 파마슈티칼스, 인코포레이티드 | 키나아제 억제제로서 포스포러스 유도체 |
PL2576541T3 (pl) | 2010-06-04 | 2016-10-31 | Pochodne aminopirymidyny jako modulatory lrrk2 | |
US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
LT3124483T (lt) | 2010-11-10 | 2019-09-25 | Genentech, Inc. | Pirazolo aminopirimidino dariniai, kaip lrrk2 moduliatoriai |
US10426761B2 (en) | 2011-04-19 | 2019-10-01 | Arms Pharmaceutical, Llc | Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof |
MX2013012151A (es) | 2011-04-19 | 2014-06-20 | ARMS Pharmaceutical LLC | Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos. |
US20130039959A1 (en) * | 2011-04-19 | 2013-02-14 | Brian Vincent Sokol | Method of inhibiting hiv and barrier-forming composition therefor |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
GB201119358D0 (en) | 2011-11-10 | 2011-12-21 | Lewi Paulus J | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
CN102675212B (zh) * | 2012-05-09 | 2014-11-05 | 昆明理工大学 | N-取代苯基-2-((1h-苯并咪唑-2-基)巯基)乙酰胺类衍生物及其用途 |
JP2016501203A (ja) | 2012-11-20 | 2016-01-18 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インドールアミン2,3−ジオキシゲナーゼの阻害剤として有用な化合物 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
JP6466107B2 (ja) * | 2014-09-04 | 2019-02-06 | 東ソー・ファインケム株式会社 | 4−フェニルチオ−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法 |
CN105085410B (zh) * | 2015-08-21 | 2017-10-10 | 武汉工程大学 | 一种二芳基嘧啶类hiv‑1抑制剂及其制备方法 |
EP3370701A1 (en) | 2015-11-06 | 2018-09-12 | INEB-Instituto Nacional De Engenharia Biomédica | A composition for use in a method for prevention or treatment of human immunodeficiency virus infections |
CN106478521A (zh) * | 2016-10-11 | 2017-03-08 | 武汉工程大学 | 一种二芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法 |
CN106866628A (zh) * | 2017-02-27 | 2017-06-20 | 武汉工程大学 | 一种芳基杂芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法 |
CN110621316B (zh) | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
CN109053613A (zh) * | 2018-07-04 | 2018-12-21 | 复旦大学 | 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途 |
EP3890486A4 (en) * | 2018-12-04 | 2022-08-03 | Virox Technologies Inc. | C3-C5 N-ALKYL GAMMA BUTYROLACTAM CONTAINING ANTIMICROBIAL COMPOSITIONS AND USES THEREOF |
US20220033851A1 (en) * | 2020-08-03 | 2022-02-03 | Roger B. Swartz | mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A. |
CA3228275A1 (en) | 2021-08-03 | 2023-02-09 | Genoveffa Franchini | Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection |
WO2023220645A1 (en) | 2022-05-10 | 2023-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vaccine for human t-lymphotropic virus-1 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4983393A (en) * | 1987-07-21 | 1991-01-08 | Maximed Corporation | Intra-vaginal device and method for sustained drug release |
FR2626002B1 (fr) | 1988-01-20 | 1994-01-28 | Regents University Minnesota | Nucleosides dideoxydidehydrocarbocycliques et composition pharmaceutique les contenant |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
JPH075570B2 (ja) | 1990-03-29 | 1995-01-25 | 三菱化学株式会社 | ピリミジンヌクレオシド誘導体及び該誘導体を有効成分とする抗ウイルス剤 |
SG49855A1 (en) * | 1990-07-19 | 1998-06-15 | Wellcome Found | Enzyme inactivators |
GB9214720D0 (en) | 1992-07-10 | 1992-08-19 | Wellcome Found | Enzyme inhibitors |
WO1995006034A1 (en) | 1993-08-24 | 1995-03-02 | Medivir Ab | Compounds and methods for inhibition of hiv and related viruses |
US6165493A (en) | 1997-10-22 | 2000-12-26 | New York Blood Center, Inc. | "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections" |
WO1999050250A1 (en) * | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Hiv inhibiting pyrimidine derivatives |
EP0945447A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
KR100658489B1 (ko) | 1998-11-10 | 2006-12-18 | 얀센 파마슈티카 엔.브이. | Hiv 복제를 억제하는 피리미딘 |
AP1636A (en) | 1998-11-10 | 2006-07-17 | Janssen Pharmaceutica Nv | 2.4-disubstituted triazine derivatives. |
US6159491A (en) * | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
AU5010800A (en) * | 1999-05-14 | 2000-12-05 | Regents Of The University Of California, The | Anti-inflammatory therapy for inflammatory mediated infection |
KR100785360B1 (ko) * | 1999-09-24 | 2007-12-18 | 얀센 파마슈티카 엔.브이. | 항바이러스 조성물 |
DE19945982A1 (de) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
US20030165540A1 (en) | 2000-05-05 | 2003-09-04 | Jen-Kuei Liu | Sentinel virus II |
WO2001085700A2 (en) * | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
ES2559273T3 (es) * | 2000-05-08 | 2016-02-11 | Janssen Pharmaceutica Nv | Profármacos de pirimidinas que inhiben la replicación del VIH |
US6596729B2 (en) | 2000-07-20 | 2003-07-22 | Bristol-Myers Squibb Company | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors |
EP1363877A2 (en) | 2001-03-02 | 2003-11-26 | SmithKline Beecham Corporation | Benzophenones as inhibitors of reverse transcriptase |
JP4959907B2 (ja) | 2001-03-27 | 2012-06-27 | ワーナー チルコット(アイルランド)リミティド | 抗菌剤投与のための膣内用ドラッグデリバリーデバイス |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
TW200306192A (en) | 2002-01-18 | 2003-11-16 | Bristol Myers Squibb Co | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
-
2003
- 2003-05-12 AR ARP030101642A patent/AR039540A1/es not_active Application Discontinuation
- 2003-05-13 DE DE60317060T patent/DE60317060T2/de not_active Expired - Lifetime
- 2003-05-13 EP EP03730208A patent/EP1505980B1/en not_active Expired - Lifetime
- 2003-05-13 EA EA200401494A patent/EA011298B1/ru unknown
- 2003-05-13 ES ES03730208T patent/ES2294291T3/es not_active Expired - Lifetime
- 2003-05-13 BR BRPI0310021A patent/BRPI0310021B8/pt not_active IP Right Cessation
- 2003-05-13 AU AU2003240844A patent/AU2003240844B2/en not_active Expired
- 2003-05-13 PL PL373840A patent/PL215128B1/pl unknown
- 2003-05-13 BR BR122014006936A patent/BR122014006936B8/pt active IP Right Grant
- 2003-05-13 DK DK03730208T patent/DK1505980T3/da active
- 2003-05-13 WO PCT/EP2003/050158 patent/WO2003094920A1/en active IP Right Grant
- 2003-05-13 CN CN201110374093.0A patent/CN102558070B/zh not_active Expired - Lifetime
- 2003-05-13 CA CA2486078A patent/CA2486078C/en not_active Expired - Lifetime
- 2003-05-13 AP AP2004003182A patent/AP2024A/xx active
- 2003-05-13 NZ NZ536976A patent/NZ536976A/en not_active IP Right Cessation
- 2003-05-13 JP JP2004503005A patent/JP4530848B2/ja not_active Expired - Lifetime
- 2003-05-13 AT AT03730208T patent/ATE376420T1/de active
- 2003-05-13 SI SI200331043T patent/SI1505980T1/sl unknown
- 2003-05-13 MX MXPA04011392A patent/MXPA04011392A/es active IP Right Grant
- 2003-05-13 KR KR1020047018312A patent/KR101095358B1/ko active IP Right Grant
- 2003-05-13 CN CN038163594A patent/CN1668305B/zh not_active Expired - Lifetime
- 2003-05-13 PT PT03730208T patent/PT1505980E/pt unknown
- 2003-05-13 US US10/514,361 patent/US7935710B2/en active Active
-
2004
- 2004-11-11 IL IL165174A patent/IL165174A/en active IP Right Grant
- 2004-12-01 NO NO20045267A patent/NO331030B1/no not_active IP Right Cessation
- 2004-12-09 ZA ZA200409984A patent/ZA200409984B/xx unknown
- 2004-12-10 HR HRP20041177AA patent/HRP20041177B1/hr not_active IP Right Cessation
-
2008
- 2008-01-22 CY CY20081100084T patent/CY1110249T1/el unknown
-
2010
- 2010-05-07 JP JP2010107209A patent/JP5256244B2/ja not_active Expired - Lifetime
-
2011
- 2011-02-22 NO NO20110298A patent/NO334067B1/no not_active IP Right Cessation
- 2011-03-08 US US13/043,174 patent/US20110165093A1/en not_active Abandoned
-
2013
- 2013-01-07 HK HK13100210.9A patent/HK1173141A1/zh not_active IP Right Cessation
-
2016
- 2016-12-23 US US15/389,662 patent/US20170100399A1/en not_active Abandoned
-
2020
- 2020-07-16 US US16/930,581 patent/US20200345733A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1173141A1 (zh) | 用於預防 性傳播的殺微生物嘧啶或三嗪 | |
HUS2200038I1 (hu) | HIV-gátló pirimidinszármazékok | |
EG24843A (en) | Herbicidal pyrimidines | |
AP2005003366A0 (en) | Pyrimidine derivatives for the prevention of HIV infection. | |
EP1546115A4 (en) | SUBSTITUTED PYRIMIDINES | |
MXPA03007166A (es) | Pirido-pirimidinas 6-sustituidas. | |
AP2005003403A0 (en) | Substituted pyrimidinones. | |
IL162189A0 (en) | Pyrimidine compounds | |
MXPA03007320A (es) | Nuevos compuestos de pirimidina. | |
MXPA03007433A (es) | Pirazolil pirimidinas. | |
GB0112802D0 (en) | Pyrimidine derivatives | |
GB0112803D0 (en) | Pyrimidine derivatives | |
GB0119477D0 (en) | Pyrimidine derivatives | |
TWI315199B (en) | Hiv replication inhibiting pyrimidines | |
GB0205214D0 (en) | Transmission pump | |
GB0112808D0 (en) | Pyrimidine derivatives | |
GB0112805D0 (en) | Pyrimidine derivatives | |
GB0112804D0 (en) | Pyrimidine derivatives | |
GB0119475D0 (en) | Pyrimidine derivatives | |
GB0112809D0 (en) | Pyrimidine derivatives | |
SI1567522T1 (sl) | Pirimidinske spojine | |
GB0124422D0 (en) | Holster | |
TW475721U (en) | Anti-robbing holster structure | |
SI1361880T1 (sl) | 6-substituirani pirido-pirimidini |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20230512 |